ClinicalTrials.gg
CompletedNCT00424372Updated Aug 27, 2021Results posted

A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia

A Phase 3 interventional study of pregabalin in Neuralgia, Postherpetic, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 33 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-27.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies testing pregabalin in Neuralgia, Postherpetic — 3 open to participants now, 3 under way, 1 of them phase 3. Pregabalin · Neuralgia, Postherpetic.

Enrollment
8th of 15
126 · median 126
Started
2007
with 2 others
Phase 3
5 of 15
1 open now
Registered
5th of 15
by date
Lead sponsor
7 of 15
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, this one is the 8th largest by enrollment, is one of 3 that started in 2007, is one of 5 in phase 3, and was the 5th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

3 of the 15 studies testing pregabalin in Neuralgia, Postherpetic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing pregabalin in Neuralgia, Postherpetic, or all of them as a file.
02

Study summary

To evaluate the safety of the long-term use of pregabalin.

03

Conditions studied

  • Neuralgia, Postherpetic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed the 13-week treatment of postherpetic neuralgia in Study A0081120.
  • Patients must be able to understand and cooperate with study procedures and have signed a written prior to entering the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who experienced serious adverse events in the preceding study (A0081120) that were determined by the investigator or the study sponsor to be causally related to the study medication.
  • Patients exhibiting treatment non-compliance in the preceding study (A0081120)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    pregabalin

    Drug: pregabalin

Interventions

  • Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks

06

What researchers measure

Primary outcomes

  1. Summary of Adverse Events

    Number of subjects with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Subjects are counted only once per treatment in each row.

    Time frame: 52 weeks

Secondary outcomes

  1. Short-Form McGill Pain Questionnaire the Efficacy of Change: Sensory Score

    Score ranges: 0-33. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

    Time frame: 52 weeks

  2. Short-Form McGill Pain Questionnaire the Efficacy of Change: Affective Score

    Score ranges: 0-12. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

    Time frame: 52 weeks

  3. Short-Form McGill Pain Questionnaire the Efficacy of Change: Total Score

    Score ranges: 0-45. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

    Time frame: 52 weeks

  4. Short-Form McGill Pain Questionnaire the Efficacy of Change: Present Pain Intensity

    Score ranges: 0-5. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

    Time frame: 52 weeks

  5. Short-Form McGill Pain Questionnaire the Efficacy of Change: Visual Analog Scale

    Ranges: 0-100 mm. Larger scale indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

    Time frame: 52 weeks

07

Results

Posted Sep 28, 2009

Participant flow

Participant flow — Overall Study
MilestonePregabalin
Started126
Completed95
Not completed31
Withdrew: Death1
Withdrew: Adverse event18
Withdrew: Lack of efficacy6
Withdrew: Withdrawal by subject4
Withdrew: Protocol violation1
Withdrew: Health deterioration1

Outcome measures

PrimarySummary of Adverse Events

Number of subjects with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Subjects are counted only once per treatment in each row.

Time frame:
52 weeks
Reported as:
Number · subjects
Summary of Adverse Events
subjectsPregabalin
Subjects with adverse events124
Subjects with serious adverse events14
Subjects with severe adverse events5
Subjects discontinued due to adverse events17
Dose reduced or temporary discontinuation34
SecondaryShort-Form McGill Pain Questionnaire the Efficacy of Change: Sensory Score

Score ranges: 0-33. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

Time frame:
52 weeks
Reported as:
Mean · score on scale
Short-Form McGill Pain Questionnaire the Efficacy of Change: Sensory Score
score on scalePregabalin
Baseline11.3 ± 7.0
Week 525.1 ± 5.6
Endpoint6.7 ± 7.1
Change from Baseline to Endpoint-4.8 ± 5.9
SecondaryShort-Form McGill Pain Questionnaire the Efficacy of Change: Affective Score

Score ranges: 0-12. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

Time frame:
52 weeks
Reported as:
Mean · score on scale
Short-Form McGill Pain Questionnaire the Efficacy of Change: Affective Score
score on scalePregabalin
Baseline3.4 ± 3.1
Week 521.0 ± 1.8
Endpoint1.7 ± 2.7
Change from Baseline to Endpoint-1.8 ± 2.8
SecondaryShort-Form McGill Pain Questionnaire the Efficacy of Change: Total Score

Score ranges: 0-45. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

Time frame:
52 weeks
Reported as:
Mean · score on scale
Short-Form McGill Pain Questionnaire the Efficacy of Change: Total Score
score on scalePregabalin
Baseline14.7 ± 9.7
Week 526.1 ± 7.2
Endpoint8.2 ± 9.6
Change from Baseline to Endpoint-6.5 ± 8.4
SecondaryShort-Form McGill Pain Questionnaire the Efficacy of Change: Present Pain Intensity

Score ranges: 0-5. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

Time frame:
52 weeks
Reported as:
Mean · score on scale
Short-Form McGill Pain Questionnaire the Efficacy of Change: Present Pain Intensity
score on scalePregabalin
Baseline2.8 ± 1.0
Week 521.4 ± 0.9
Endpoint1.7 ± 1.1
Change from Baseline to Endpoint-1.1 ± 1.1
SecondaryShort-Form McGill Pain Questionnaire the Efficacy of Change: Visual Analog Scale

Ranges: 0-100 mm. Larger scale indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.

Time frame:
52 weeks
Reported as:
Mean · mm
Short-Form McGill Pain Questionnaire the Efficacy of Change: Visual Analog Scale
mmPregabalin
Baseline62.0 ± 19.0
Week 5228.3 ± 22.9
Endpoint33.7 ± 25.6
Change from Baseline to Endpoint-28.3 ± 23.8

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—15/126 (11.9%)98/126 (77.8%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPregabalin
Spinal compression fractureInjury, poisoning and procedural complications2/126
Atrial fibrillationCardiac disorders1/126
Cardiac failure congestiveCardiac disorders1/126
VertigoEar and labyrinth disorders1/126
Gastroduodenal ulcerGastrointestinal disorders1/126
Chest painGeneral disorders1/126
PneumoniaInfections and infestations1/126
Heat strokeInjury, poisoning and procedural complications1/126
Joint dislocationInjury, poisoning and procedural complications1/126
Open fractureInjury, poisoning and procedural complications1/126
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPregabalin
DizzinessNervous system disorders36/126
NasopharyngitisInfections and infestations34/126
Oedema peripheralGeneral disorders22/126
SomnolenceNervous system disorders22/126
Weight increasedInvestigations19/126
ConstipationGastrointestinal disorders12/126
DiarrhoeaGastrointestinal disorders12/126
FallInjury, poisoning and procedural complications9/126
Retinal haemorrhageEye disorders7/126
Visual acuity reducedEye disorders7/126

Baseline characteristics

Age, Customized
Age, Customized(Subjects)Pregabalin
>= 18 and < 45 years1
>= 45 and < 65 years19
>=65 years106
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin
Female55
Male71
08

Study locations

33 sites
  • National Hospital Organization Nagoya Medical Center
    Nagoya, Aichi 460-0001, Japan
  • Kobayashi Clinic
    Urayasu, Chiba 279-0012, Japan
  • Okabe Hospital
    Kasuya-gun, Fukuoka 811-2122, Japan
  • Gunma Pain Clinic Hospital
    Maebashi, Gunma 379-2147, Japan
  • Takasaki Pain Clinic
    Takasaki, Gunma 370-0035, Japan
  • Asahikawa Pain Clinic Hospital
    Asahikawa, Hokkaido 070-0034, Japan
  • Kamui Pain Clinic
    Asahikawa, Hokkaido 070-8013, Japan
  • Sapporo Asabu Clinic
    Sapporo, Hokkaido 001-0045, Japan
  • Higashi Sapporo Hospital
    Sapporo, Hokkaido 003-8585, Japan
  • Seimei Clinic
    Akashi, Hyogo 673-0016, Japan
  • Uchida Pain Relief Clinic
    Amagasaki, Hyogo 661-0012, Japan
  • National Hospital Organization Himeji Medical Center
    Himeji, Hyogo 670-8520, Japan
  • National Hospital Organization Kobe Medical Center
    Kobe, Hyogo 654-0155, Japan
  • Nakamura Clinic
    Kobe, Hyogo 655-0854, Japan
  • National Hospital Organization Sagamihara National Hospital
    Sagamihara, Kanagawa 228-8522, Japan
  • Suzuki Pain Clinic
    Yokohama, Kanagawa 227-0043, Japan
  • Hajiri Pain Clinic
    Yokohama, Kanagawa 236-0037, Japan
  • National Hospital Organization Yokohama Medical Center
    Yokohama, Kanagawa 245-8575, Japan
  • Sendai Pain Clinic
    Sendai, Miyagi 983-0036, Japan
  • Nakamura Hospital
    Beppu, Ohita 874-0937, Japan
  • Kawaguchi Kogyo General Hospital
    Kawaguchi, Saitama 332-0031, Japan
  • Kinoshita Clinic
    Tokorozawa, Saitama 359-0038, Japan
  • Tokyo Women's Medical University Center East
    Arakawa-ku, Tokyo 116-8567, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Mitaka Pain Clinic
    Mitaka, Tokyo 181-0013, Japan
  • Toriumi Pain Clinic
    Nakano-ku, Tokyo 165-0027, Japan
  • Kanto Medical NTT East Corporation
    Shinagawa-ku, Tokyo 141-0022, Japan
  • Naganuma Pain Clinic
    Shinagawa-ku, Tokyo 141-0022, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo 162-8666, Japan
  • Mukai Clinic
    Fukuoka, 812-0011, Japan
  • KM Pain Clinic
    Fukuoka, 814-0001, Japan
  • Otsuki Sleep Clinic
    Fukushima, 960-8044, Japan
  • Hasumi Pain Clinic
    Saitama, 330-0805, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2007 to primary completion in Aug 2008, 19 months.

Results were first posted in Sep 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2007
First posted
Jan 19, 2007
StartActual
Jan 12, 2007
Primary completionActual
Aug 19, 2008
CompletionActual
Aug 19, 2008
Results first posted
Sep 28, 2009
Last update
Aug 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00424372
Responsible party
Sponsor
First posted
Jan 19, 2007
Start date
Jan 12, 2007
Primary completion
Aug 19, 2008
Completion
Aug 19, 2008
Results posted
Sep 28, 2009
Last update
Aug 27, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion